Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2025-11-12 00:00:00 ET · period of report 2025-11-10 · accession 0001583098-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-12 | 2025-11-10 | EBS | DeGolyer Donald W | Dir | S - Sale | $10.54 | -17.8K | 119.9K | -13% | -$187.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-10 | S | D | 17,801 | $10.54 | 119,858 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2025. (F2) For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.33 - $10.79. The Company maintains a record of the transactions and copies will be provided upon request. |